Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
China Pharma Holdings Inc (CPHI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CPHI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -82.7% | Avg. Invested days 16 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.96M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) - | Beta 0.75 | 52 Weeks Range 1.20 - 3.35 | Updated Date 06/29/2025 |
52 Weeks Range 1.20 - 3.35 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.22 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -106.3% | Operating Margin (TTM) -66.76% |
Management Effectiveness
Return on Assets (TTM) -18.22% | Return on Equity (TTM) -59.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9050107 | Price to Sales(TTM) 1.39 |
Enterprise Value 9050107 | Price to Sales(TTM) 1.39 | ||
Enterprise Value to Revenue 2.11 | Enterprise Value to EBITDA -225.89 | Shares Outstanding 3262000 | Shares Floating 2640623 |
Shares Outstanding 3262000 | Shares Floating 2640623 | ||
Percent Insiders 30.26 | Percent Institutions 1.04 |
Upturn AI SWOT
China Pharma Holdings Inc
Company Overview
History and Background
China Pharma Holdings, Inc. was founded in 1995. It focuses on research, development, manufacturing, and sales of pharmaceutical products in China.
Core Business Areas
- Generic Drugs: Manufactures and distributes generic pharmaceutical products. These include treatments for cardiovascular and cerebrovascular diseases, central nervous system diseases, and other common ailments.
- Traditional Chinese Medicine (TCM): Produces and markets TCM products, leveraging traditional formulations and manufacturing processes.
Leadership and Structure
Leadership consists of a CEO and a board of directors. The organizational structure includes departments for R&D, manufacturing, sales, marketing, and finance.
Top Products and Market Share
Key Offerings
- Xinnaoning: A cerebrovascular drug. Market share data is difficult to ascertain precisely due to the fragmented nature of the Chinese pharmaceutical market. Competitors include local Chinese pharma companies specializing in cerebrovascular treatments. Revenue contributions are undisclosed.
- Xuesaitong Soft Capsules: Traditional Chinese Medicine product for cardiovascular health. Market share data is unavailable. Competitors include other TCM manufacturers. Revenue contributions are undisclosed.
Market Dynamics
Industry Overview
The Chinese pharmaceutical market is large and growing, driven by an aging population and increasing healthcare spending. It is characterized by intense competition, regulatory changes, and a push for innovation.
Positioning
China Pharma Holdings is a smaller player in the Chinese pharmaceutical market, focusing on generic drugs and TCM. Competitive advantages include established distribution networks and local market knowledge.
Total Addressable Market (TAM)
The Chinese pharmaceutical market is estimated to be worth hundreds of billions of dollars annually. China Pharma Holdings' position is a small fraction of this TAM, suggesting significant growth potential but also substantial competition.
Upturn SWOT Analysis
Strengths
- Established distribution network in China
- Experience in generic drug manufacturing
- Knowledge of local market conditions
- Production of Traditional Chinese Medicine products
Weaknesses
- Smaller scale compared to larger pharmaceutical companies
- Limited R&D capabilities
- Dependence on generic drug market
- Financial Constraints
Opportunities
- Expanding healthcare coverage in China
- Increasing demand for generic drugs
- Growing interest in Traditional Chinese Medicine
- Strategic partnerships with other companies
Threats
- Intense competition from domestic and international players
- Stringent regulatory requirements
- Price pressures on generic drugs
- Intellectual property infringement
Competitors and Market Share
Key Competitors
- SNY
- MRK
- PFE
Competitive Landscape
China Pharma Holdings faces significant competition. Larger companies have greater resources for R&D, marketing, and distribution. China Pharma's advantages lie in its local market knowledge and focus on generic drugs and TCM.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data requires specific financial data which is currently not readily available to be accurately inserted here.
Future Projections: Future growth projections are not readily available and depend on market conditions and company performance.
Recent Initiatives: Recent strategic initiatives require specific financial data which is currently not readily available to be accurately inserted here.
Summary
China Pharma Holdings is a small player in the competitive Chinese pharmaceutical market. It leverages generic drugs and TCM for revenue. Its smaller scale and limited R&D create a struggle. It needs to capitalize on market opportunities and manage competitive pressures to be successful.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Market research reports
Disclaimers:
The information provided is based on available public data and may not be entirely accurate or complete. Market share data is estimated. Financial data may be outdated or unavailable. This analysis is for informational purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About China Pharma Holdings Inc
Exchange NYSE MKT | Headquaters - | ||
IPO Launch date 2002-04-17 | President, CEO, Chairman & Interim CFO Ms. Zhilin Li | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 224 | |
Full time employees 224 | |||
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets. It offers Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People's Republic of China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.